TY - JOUR
T1 - Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines
AU - Kumar, Shaji K.
AU - Callander, Natalie S.
AU - Hillengass, Jens
AU - Liedtke, Michaela
AU - Baljevic, Muhamed
AU - Campagnaro, Erica
AU - Castillo, Jorge J.
AU - Chandler, Jason C.
AU - Cornell, Robert F.
AU - Costello, Caitlin
AU - Efebera, Yvonne
AU - Faiman, Matthew
AU - Garfall, Alfred
AU - Godby, Kelly
AU - Holmberg, Leona
AU - Htut, Myo
AU - Huff, Carol Ann
AU - Kang, Yubin
AU - Landgren, Ola
AU - Malek, Ehsan
AU - Martin, Thomas
AU - Omel, James
AU - Raje, Noopur
AU - Sborov, Douglas
AU - Singhal, Seema
AU - Stockerl-Goldstein, Keith
AU - Tan, Carlyn
AU - Weber, Donna
AU - Johnson-Chilla, Alyse
AU - Keller, Jennifer
AU - Kumar, Rashmi
N1 - Funding Information:
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.
Funding Information:
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Publisher Copyright:
© 2019. All rights reserved.
PY - 2019
Y1 - 2019
N2 - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.
AB - The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.
UR - http://www.scopus.com/inward/record.url?scp=85072968604&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2019.0049
DO - 10.6004/jnccn.2019.0049
M3 - Review article
C2 - 31590151
AN - SCOPUS:85072968604
SN - 1540-1405
VL - 17
SP - 1154
EP - 1165
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 10
ER -